| 0.618 0.082 (15.28%) | 11-28 13:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.99 | 1-year : | 1.27 |
| Resists | First : | 0.85 | Second : | 1.09 |
| Pivot price | 0.63  |
|||
| Supports | First : | 0.47 | Second : | 0.39 |
| MAs | MA(5) : | 0.53  |
MA(20) : | 0.68 |
| MA(100) : | 0.86 |
MA(250) : | 1.8 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 26 |
D(3) : | 19 |
| RSI | RSI(14): 39.7 |
|||
| 52-week | High : | 6.53 | Low : | 0.47 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ YCBD ] has closed above bottom band by 44.6%. Bollinger Bands are 15.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.84 - 0.85 | 0.85 - 0.85 |
| Low: | 0.53 - 0.53 | 0.53 - 0.54 |
| Close: | 0.53 - 0.54 | 0.54 - 0.54 |
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids. It also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name. The company distributes its products through its e-commerce Website, third-party e-commerce sites, wholesalers, and various brick and mortar retailers in the United States. It has a research partnership with the University of Mississippi to identify novel cannabinoids. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. was incorporated in 2015 and is headquartered in Charlotte, North Carolina.
Sat, 29 Nov 2025
cbdMD Signs New Executive Employment Agreement - The Globe and Mail
Fri, 28 Nov 2025
cbdMD (NYSE: YCBD) sets 2025 equity compensation plan and CEO pay terms - Stock Titan
Fri, 21 Nov 2025
cbdMD Reports Preliminary Unaudited Fourth Quarter and Fiscal 2025 Results - PR Newswire
Thu, 09 Oct 2025
cbdMD's Herbal Oasis Expands its Florida Footprint with Bevtalk Distribution Partnership - PR Newswire
Wed, 01 Oct 2025
cbdMD, Inc. Announces Closing of $1.7 Million Series B Preferred Private Placement - Newsfile
Thu, 25 Sep 2025
cbdMD Announces Inferno Freeze: Our Most Powerful Topical - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 9 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 16 (%) |
| Held by Institutions | 5.4 (%) |
| Shares Short | 68 (K) |
| Shares Short P.Month | 42 (K) |
| EPS | 0.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.68 |
| Profit Margin | -8 % |
| Operating Margin | -19.7 % |
| Return on Assets (ttm) | -9.5 % |
| Return on Equity (ttm) | -33.2 % |
| Qtrly Rev. Growth | -11 % |
| Gross Profit (p.s.) | 1.3 |
| Sales Per Share | 2.13 |
| EBITDA (p.s.) | -0.08 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | 1.19 |
| PEG Ratio | 0 |
| Price to Book value | 0.88 |
| Price to Sales | 0.28 |
| Price to Cash Flow | -5.22 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|